Back

Efficacy of the PCSK9 inhibitor for lipid-rich coronary plaque reduction: a near-infrared spectroscopy analysis

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Intravascular imaging and physiology to optimise outcomes Intracoronary Ultrasound ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Hideaki Ota

Fujita Health University, Toyoake (Japan)

7 More presentations in this session

Presentation thumbnail
A novel parameter for stent expansion is superior to conventional parameters for predicting adverse events after drug-eluting stent implantation
Doctor A. Katsura (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
OCT guidance during primary PCI may increase long-term risk of device oriented events: subanalysis of ROBUST study
Doctor M. Jakl (Brno, CZ)
Abstract Slides Video
Presentation thumbnail
Optical coherence tomography derived predictors of restenosis after non-stenting coronary intervention with drug-coated balloon
Doctor S. Nakagama (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Usefulness of the trans-stent fractional flow reserve gradient for predicting clinical outcomes
Professor H. Lim (Suwon, KR)
Abstract Slides Video
Presentation thumbnail
Gender differences in long-term outcomes in patients with deferred revascularization following fractional flow reserve assessment: international collaboration registry of physiologic evaluation
Doctor M. Hoshino (Amsterdam, NL)
Abstract

Access the full session

Session thumbnail
Intravascular imaging and physiology to optimise outcomes

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Intracoronary imaging: from research tool to class IA in the Guidelines
thumbnail
Congress Presentation
Optical coherence tomography and intravascular ultrasound: which is the best technique in different scenarios?
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources